Print

Celgene International Sárl (CELG) Release: Phase III Study with REVLIMID® Continuous Therapy Demonstrates Statistically Significant Improvement in Progression-Free Survival for Patients Newly Diagnosed with Multiple Myeloma  
12/13/2011 6:23:03 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that data from the planned interim analysis of MM-015, a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) therapy for the treatment of patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplant, reported a clinically significant improvement in progression-free survival (PFS), the primary endpoint of the study. The data, presented at the 53rd Annual Meeting of the American Society of Hematology, focused on a pre-specified sub-analysis of patients who were 75 years or younger.
//-->